ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

deucravacitinib

Also written as “BMS-986165”, “Deucravacitinib” and “BMS-986165 Tablet”.

Its studies are mostly in Psoriasis · Lupus Erythematosus, Systemic · Arthritis, Psoriatic · Crohn Disease · Colitis, Ulcerative, led by 2 companies.

Drug pageDeucravacitinib: every studyAll 78 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Jul 27, 202260 company-led studies, 12 open or runningNext primary completion: Nov 18, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bristol-Myers Squibbits history only5912 open or runningphase 4since Jul 27, 2022Oct 3, 2016Nov 18, 2026phase 3 · NCT05946941
AbbVie10 open or runningphase 4since Mar 21, 2024Mar 21, 2024none ahead

Also a collaborator on its studies: Covance.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of AbbVie only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Jun 9, 2020Named deucravacitinibINNProposed as its International Nonproprietary Name in WHO's List 123 · before, BMS-986165
  2. Mar 21, 2024First study: phase 4 study in Moderate Plaque PsoriasisFirst studyNCT06333860 · 393 enrolled · United States, Australia, Belgium and more

TargetBeta

TYK2 →read by rule
“Tyrosine-protein kinase TYK2 negative allosteric modulator”ChEMBL 37, by rule

Other programs on TYK2

ProgramCompanyFurthest phaseStudies
ruxolitinibruleIncytephase 495
tofacitinibrulePfizerphase 494
upadacitinibruleAbbViephase 464
filgotinib maleateruleEisaiphase 42
filgotinibruleLakefront Biotherapeutics NVphase 346
brepocitinibrulePfizerphase 325
delgocitinibruleLEO Pharmaphase 321
D-2570ruleInventisBiophase 313
HS-10374Hansoh Pharmaceutical Groupphase 36
TQH3906Sino Biopharmaceuticalphase 36
FXS5626Fosun Pharmaphase 33
TYK2 Inhibitorruleusynova-pharmaceuticals-ltdno phase1

Studies

The one study AbbVie leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06333860Moderate Plaque Psoriasis · United States, Australia, Belgium and more4CompletedMar 19, 2026393

How it is read

Names in the registry

  • “BMS-986165”, 34 entries
  • “Deucravacitinib”, 21 entries
  • “BMS-986165 Tablet”, 2 entries
  • “BMS-986165 Dose A”, 1 entry
  • “BMS-986165 Dose B”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.